PriceTargets.com logo

Kronos Bio - KRON Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $1.63
  • Forecasted Upside: 69.64%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.96 As of 12/20/2024 06:16 PM ET
▲ +0.0298 (3.21%)

This chart shows the closing price for KRON by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kronos Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KRON and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KRON

Analyst Price Target is $1.63
▲ +69.64% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Kronos Bio in the last 3 months. The average price target is $1.63, with a high forecast of $2.25 and a low forecast of $1.00. The average price target represents a 69.64% upside from the last price of $0.96.

This chart shows the closing price for KRON for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 investment analysts is to hold stock in Kronos Bio. This rating has held steady since October 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2024Piper SandlerDowngradeOverweight ➝ Neutral$6.00 ➝ $1.00
11/14/2024TD CowenDowngradeBuy ➝ Hold
10/8/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$6.00 ➝ $6.00
8/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$2.25 ➝ $2.25
8/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$2.25 ➝ $2.25
5/3/2024HC WainwrightLower TargetBuy ➝ Buy$2.50 ➝ $2.25
12/19/2023HC WainwrightLower TargetBuy ➝ Buy$9.00 ➝ $2.50
12/19/2023Piper SandlerLower TargetOverweight ➝ Overweight$7.00 ➝ $6.00
11/27/2023HC WainwrightReiterated RatingBuy ➝ Buy$9.00
8/21/2023HC WainwrightLower TargetBuy ➝ Buy$10.00 ➝ $9.00
4/17/2023HC WainwrightReiterated RatingBuy$10.00
11/18/2022HC WainwrightLower TargetBuy$36.00 ➝ $10.00
11/10/2022The Goldman Sachs GroupLower TargetBuy$25.00 ➝ $14.00
11/9/2022Piper SandlerLower TargetOverweight$13.00 ➝ $7.00
9/14/2022Berenberg BankInitiated CoverageBuy$12.00
5/24/2022The Goldman Sachs GroupLower TargetBuy$35.00 ➝ $23.00
5/23/2022Piper SandlerLower TargetOverweight$30.00 ➝ $13.00
3/8/2022HC WainwrightReiterated RatingBuy$36.00
2/27/2022Piper SandlerLower TargetOverweight$50.00 ➝ $30.00
11/10/2021HC WainwrightBoost TargetBuy$35.00 ➝ $36.00
10/20/2021CowenInitiated CoverageOutperform
6/24/2021HC WainwrightInitiated CoverageBuy$35.00
11/3/2020CowenInitiated CoverageOutperform
11/3/2020Jefferies Financial GroupInitiated CoverageBuy$36.00
11/3/2020The Goldman Sachs GroupInitiated CoverageBuy$45.00
11/3/2020Piper SandlerInitiated CoverageOverweight$50.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.02 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024
  • 0 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 0 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Kronos Bio logo
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Read More

Today's Range

Now: $0.96
Low: $0.92
High: $0.97

50 Day Range

MA: $0.94
Low: $0.83
High: $1.07

52 Week Range

Now: $0.96
Low: $0.69
High: $1.60

Volume

78,382 shs

Average Volume

278,920 shs

Market Capitalization

$57.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Kronos Bio?

The following Wall Street sell-side analysts have issued research reports on Kronos Bio in the last year: HC Wainwright, Piper Sandler, and TD Cowen.
View the latest analyst ratings for KRON.

What is the current price target for Kronos Bio?

0 Wall Street analysts have set twelve-month price targets for Kronos Bio in the last year. Their average twelve-month price target is $1.63, suggesting a possible upside of 69.6%. HC Wainwright has the highest price target set, predicting KRON will reach $2.25 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $1.00 for Kronos Bio in the next year.
View the latest price targets for KRON.

What is the current consensus analyst rating for Kronos Bio?

Kronos Bio currently has 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in KRON, but not buy more shares or sell existing shares.
View the latest ratings for KRON.

What other companies compete with Kronos Bio?

Other companies that are similar to Kronos Bio include Atai Life Sciences, Tenaya Therapeutics, SOPHiA GENETICS, Acrivon Therapeutics and Aclaris Therapeutics. Learn More about companies similar to Kronos Bio.

How do I contact Kronos Bio's investor relations team?

The company's listed phone number is 650-781-5200 and its investor relations email address is [email protected]. The official website for Kronos Bio is kronosbio.com. Learn More about contacing Kronos Bio investor relations.